Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Non-Current Deferred Tax Liability (2022 - 2024)

Historic Non-Current Deferred Tax Liability for ProQR Therapeutics (PRQR) over the last 3 years, with Q4 2024 value amounting to $3.2 million.

  • ProQR Therapeutics' Non-Current Deferred Tax Liability fell 2180.78% to $3.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.2 million, marking a year-over-year decrease of 2180.78%. This contributed to the annual value of $3.2 million for FY2024, which is 2122.52% down from last year.
  • ProQR Therapeutics' Non-Current Deferred Tax Liability amounted to $3.2 million in Q4 2024, which was down 2180.78% from $4.0 million recorded in Q4 2023.
  • ProQR Therapeutics' 5-year Non-Current Deferred Tax Liability high stood at $4.0 million for Q4 2023, and its period low was $3.2 million during Q4 2024.
  • For the 3-year period, ProQR Therapeutics' Non-Current Deferred Tax Liability averaged around $3.7 million, with its median value being $3.8 million (2022).
  • As far as peak fluctuations go, ProQR Therapeutics' Non-Current Deferred Tax Liability soared by 574.09% in 2023, and later tumbled by 2180.78% in 2024.
  • ProQR Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $3.8 million in 2022, then grew by 5.74% to $4.0 million in 2023, then dropped by 21.81% to $3.2 million in 2024.
  • Its Non-Current Deferred Tax Liability was $3.2 million in Q4 2024, compared to $4.0 million in Q4 2023 and $3.8 million in Q4 2022.